{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T01:27:18Z","timestamp":1783560438050,"version":"3.55.0"},"reference-count":45,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Therapy"],"published-print":{"date-parts":[[2015,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Direct-acting antivirals (DAAs) are predicted to transform hepatitis C therapy, yet little is known about the prevalence of naturally occurring resistance mutations in recently acquired HCV. This study aimed to determine the prevalence and frequency of drug resistance mutations in the viral quasispecies among HIV-positive and -negative individuals with recent HCV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The NS3 protease, NS5A and NS5B polymerase genes were amplified from 50 genotype 1a participants of the Australian Trial in Acute Hepatitis C. Amino acid variations at sites known to be associated with possible drug resistance were analysed by ultra-deep pyrosequencing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 12% of individuals harboured dominant resistance mutations, while 36% demonstrated non-dominant resistant variants below that detectable by bulk sequencing (that is, &lt;20%) but above a threshold of 1%. Resistance variants (&lt;1%) were observed at most sites associated with DAA resistance from all classes, with the exception of sofosbuvir.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Dominant resistant mutations were uncommonly observed in the setting of recent HCV. However, low-level mutations to all DAA classes were observed by deep sequencing at the majority of sites and in most individuals. The significance of these variants and impact on future treatment options remains to be determined. Clinicaltrials.gov NCT00192569.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3851\/imp2821","type":"journal-article","created":{"date-parts":[[2014,8,8]],"date-time":"2014-08-08T11:03:34Z","timestamp":1407495814000},"page":"199-208","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":21,"title":["Naturally Occurring Dominant Drug Resistance Mutations Occur Infrequently in the Setting of Recently Acquired Hepatitis C"],"prefix":"10.1177","volume":"20","author":[{"given":"Tanya L","family":"Applegate","sequence":"first","affiliation":[{"name":"The Kirby Institute, UNSW Australia, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Gaudieri","sequence":"additional","affiliation":[{"name":"School of Anatomy, Physiology and Human Biology, University of Western Australia, Perth, Australia"},{"name":"Institute for Immunology and Infectious Diseases, Murdoch University, Perth, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Plauzolles","sequence":"additional","affiliation":[{"name":"Centre for Forensic Science, University of Western Australia, Perth, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abha","family":"Chopra","sequence":"additional","affiliation":[{"name":"Institute for Immunology and Infectious Diseases, Murdoch University, Perth, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Grebely","sequence":"additional","affiliation":[{"name":"The Kirby Institute, UNSW Australia, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Lucas","sequence":"additional","affiliation":[{"name":"Institute for Immunology and Infectious Diseases, Murdoch University, Perth, Australia"},{"name":"School of Medicine and School of Pathology & Laboratory Medicine, University of Western Australia, Perth, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Hellard","sequence":"additional","affiliation":[{"name":"Macfarlane Burnett Institute for Population Health, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Luciani","sequence":"additional","affiliation":[{"name":"Inflammation and Infection Research Centre, UNSW Australia, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J","family":"Dore","sequence":"additional","affiliation":[{"name":"The Kirby Institute, UNSW Australia, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail V","family":"Matthews","sequence":"additional","affiliation":[{"name":"The Kirby Institute, UNSW Australia, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2015,2,1]]},"reference":[{"key":"bibr1-IMP2821","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21781"},{"key":"bibr2-IMP2821","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.02.037"},{"key":"bibr3-IMP2821","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2009.01124.x"},{"key":"bibr4-IMP2821","doi-asserted-by":"publisher","DOI":"10.1007\/s11538-012-9736-y"},{"key":"bibr5-IMP2821","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22549"},{"key":"bibr6-IMP2821","doi-asserted-by":"publisher","DOI":"10.1086\/596657"},{"key":"bibr7-IMP2821","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22122"},{"key":"bibr8-IMP2821","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22773"},{"key":"bibr9-IMP2821","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12051"},{"key":"bibr10-IMP2821","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(11)60069-X"},{"key":"bibr11-IMP2821","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0024907"},{"key":"bibr12-IMP2821","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.06627-11"},{"key":"bibr13-IMP2821","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0069698"},{"key":"bibr14-IMP2821","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00838-12"},{"key":"bibr15-IMP2821","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2013.08.001"},{"key":"bibr16-IMP2821","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2632"},{"key":"bibr17-IMP2821","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2013.09.022"},{"key":"bibr18-IMP2821","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.09.019"},{"key":"bibr19-IMP2821","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23101"},{"key":"bibr20-IMP2821","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002243"},{"key":"bibr21-IMP2821","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1177\/135965350501000409","volume":"10","author":"John M.","year":"2005","journal-title":"Antivir Ther"},{"key":"bibr22-IMP2821","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1419"},{"key":"bibr23-IMP2821","doi-asserted-by":"publisher","DOI":"10.1086\/591141"},{"key":"bibr24-IMP2821","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-9-245"},{"key":"bibr25-IMP2821","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr581"},{"key":"bibr26-IMP2821","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1010494"},{"key":"bibr27-IMP2821","unstructured":"Merck and Co. I. FDA Antiviral Drugs Advisory Committee Meeting boceprevir capsules (NDA 202-258) Briefing Document. 2011. (Accessed 18 January 2014.) Available from www.fda.gov\/downloads\/advisoryCommittees\/committeemeetingmaterial\/drugs\/antiviraldrugscommittee\/UCM252343.pdf."},{"key":"bibr28-IMP2821","doi-asserted-by":"crossref","unstructured":"Jacobson I., Dore G.J., Foster G.R. Simeprevir (TMC435) with peginterferon\/ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naive patients: efficacy in difficult-to-treat patient sub-populations in the QUEST 1 and 2 Phase III trial.\n                      64th Annual Meeting of the American Association for the Study of Liver diseases\n                      . 1\u20135 November 2013, Washington, DC, USA. Abstract 1122.","DOI":"10.1016\/S0168-8278(13)61424-5"},{"key":"bibr29-IMP2821","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01976-13"},{"key":"bibr30-IMP2821","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2011.08.015"},{"key":"bibr31-IMP2821","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2013.05.013"},{"key":"bibr32-IMP2821","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01035-12"},{"key":"bibr33-IMP2821","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02494-12"},{"key":"bibr34-IMP2821","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.05842-11"},{"key":"bibr35-IMP2821","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2013.107"},{"key":"bibr36-IMP2821","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2011.32"},{"key":"bibr37-IMP2821","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2012.09.013"},{"key":"bibr38-IMP2821","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/673240"},{"key":"bibr39-IMP2821","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002880"},{"key":"bibr40-IMP2821","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328363b1f9"},{"key":"bibr41-IMP2821","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.10.056"},{"key":"bibr42-IMP2821","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.11.035"},{"key":"bibr43-IMP2821","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0005683"},{"key":"bibr44-IMP2821","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3000544"},{"key":"bibr45-IMP2821","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1110064108"}],"container-title":["Antiviral Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP2821","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP2821","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:52:06Z","timestamp":1777380726000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3851\/IMP2821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["10.3851\/IMP2821"],"URL":"https:\/\/doi.org\/10.3851\/imp2821","relation":{},"ISSN":["1359-6535","2040-2058"],"issn-type":[{"value":"1359-6535","type":"print"},{"value":"2040-2058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2]]}}}